University of Michigan forms chronic kidney disease consortium with pharma companies
The University of Michigan has established a chronic kidney disease (CKD) consortium with several pharmaceutical companies, including AstraZeneca and Eli Lilly and Company.
The Renal Pre-Competitive Consortium (RPC2) will develop and utilize large-scale data exploration to find new treatment targets for CKD.
Click on this link for more information.
